CYAD-231

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCYAD-231

Drug Alias Namedual anti-NKG2D-ligand/undisclosed CAR T-cell therapy (Celyad Oncology)dual anti-NKG2D-ligand/undisclosed CAR T-cell therapy (Celyad Oncology)CYAD-231

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionNKG2D ligands modulators

TargetsNKG2D ligands

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCelyad Oncology SA

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelyad Oncology SA

Active IndicationsN/A

Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A